Results 141 to 150 of about 19,721 (235)

Autonomic Nervous System Phenotyping Across Chronic Demyelinating Peripheral Neuropathies: A Comparative Study

Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Background and Aims This study aimed to systematically phenotype autonomic nervous system (ANS) involvement in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), monoclonal gammopathy of undetermined significance‐associated neuropathy (MGUS‐PNP), Charcot–Marie–Tooth disease Type 1A (CMT1A), and hereditary neuropathy with ...
Bogdan Bjelica, Teodora Todorovic, Ivo Bozovic, Aleksa Palibrk, Vladimir Jankovic, Ivana Basta, Stojan Peric   +6 more
wiley   +1 more source

CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX‐5+ Tumour‐Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 341-352, June 2026.
ABSTRACT Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision‐making.
Fernanda Ramalho Ramos, Janayna Maria Parente Serafim, Bethânia Almeida Gouveia, Pedro Luiz Porfirio Xavier, Juliano Rodrigues Sangalli, Heidge Fukumasu, Ricardo de Francisco Strefezzi   +6 more
wiley   +1 more source

Obligate and facultative paraneoplastic dermatoses: an overview

Dermatology Practical & Conceptual, 2018
Dermatological paraneoplastic syndromes are a group of cutaneous diseases associated with malignancy, but not directly related to the primary tumor itself or to its metastases.
Stefano Caccavale, Gabriella Brancaccio, Marina Agozzino, Paola Vitiello, Roberto Alfano, Giuseppe Argenziano   +5 more
doaj  

Tumoral parkinsonism-Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. [PDF]

Brain Behav, 2023
Cedergren Weber G, Timpka J, Rydelius A, Bengzon J, Odin P.   +4 more
europepmc   +1 more source

Paraneoplastic syndromes: what we know and what we should know

, 2006
Paraneoplastic syndromes are a group of clinical disorders associated with malignant diseases that are not directly related to the physical effects of primary or metastatic tumor.
Santini D, Vincenzi B, Tonini G
core  

Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes

Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour immunity, can trigger neurological adverse events closely resembling paraneoplastic neurological syndromes.
Zekeridou A., Villagran-Garcia M., Vogrig A., Velasco R., Muniz-Castrillo S., Honnorat J., Farina A., Guidon A. C., Joubert B.   +8 more
core   +1 more source

Clinical characteristics of paraneoplastic syndromes in patients with head and neck cancer. [PDF]

Laryngoscope Investig Otolaryngol, 2022
Diao W, Liang Y, Gao L, Zhu Y, Zhu X, Yu S, Xia X, Chen X, Chen X.   +8 more
europepmc   +1 more source

Paraneoplastic Syndromes in Patients with Keratinocyte Skin Cancer. [PDF]

Cancers (Basel), 2022
Vlachos C, Tziortzioti C, Bassukas ID.
europepmc   +1 more source

Paraneoplastic syndromes related to neuroendorine tumours

, 2017
Low or high grade malignant neoplasms present syndromes secondary to symptoms related to local mass effects to surrounding structures or through the development of metastases.
Grossman, Ashley, Androulakis, Ioannis I., Kaltsas, Gregory, Dimitriadis, Georgios K.   +3 more
core  

Reversal of rare paraneoplastic syndromes in melanoma: fever and cutaneous melanosis. [PDF]

Melanoma Res
van Geel JJL, Obihara NJ, van Rens DH, Boers-Sonderen MJ, Bonenkamp JJ, Bol KF.   +5 more
europepmc   +1 more source